CD25/IL-2R alpha Antibody (Basiliximab) - Chimeric - Azide and BSA Free, Novus Biologicals™

CD25/IL-2 R alpha

Monoclonal

Unconjugated

PBS with 0.02% Proclin 300. with 0.02% Proclin 300

IL2RA

CD25

0.2 mg

Adaptive Immunity, Apoptosis, B Cell Development and Differentiation Markers, Cytokine Research, Diabetes Research, Immunology, Innate Immunity, Mast Cell Markers, Signal Transduction

3559

Human, Mouse, Rat

Purified

Western Blot, Flow Cytometry, Immunohistochemistry, Blocking Assay, Immunofluorescence, CyTOF

Basiliximab

Western Blot 1:100 - 1:2000, Flow Cytometry 1:10 - 1:1000, Immunohistochemistry 1:10 - 1:500, Blocking/Neutralizing 50 - 200 molar excess, Immunofluorescence 1:10 - 1:500, CyTOF-ready

CD25, CD25 antigen, IDDM10, IL-2 receptor subunit alpha, IL2R, IL-2R subunit alpha, IL-2-RA, IL2-RA, interleukin 2 receptor, alpha, interleukin-2 receptor subunit alpha, p55, TAC antigen, TCGFR

Rabbit

Protein A or G purified

RUO

Primary

Basiliximab recognises the human IL-2R and binds to the epitope (116)ERIYHFV(122) within the extracellular domain of the CD25 subunit - binding is abolished when 2 or more residues within the epitope are mutated. This epitope overlaps with the interaction site of CD25 and IL-2. CD25 is found in the high-affinity IL-2R ( alpha beta yc) - T cells only express CD25 upon activation. IL-2 binding to IL-2R on T cells modulates proliferation and differentiation.

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

IgG